Table 2 Observed and estimated prevalence of HCV exposure and chronic HCV infection
From: Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study
Age (years) | Invited | Tested | Observed HCV exposure (n) | Prevalence of HCV exposure (% (95% CI)) | Estimated HCV exposure* (n) | Observed chronic (viraemic) HCV infection (n) | Prevalence of chronic (viraemic) HCV infection (% (95% CI)) | Estimated chronic (viraemic) HCV infectiona (n) |
|---|---|---|---|---|---|---|---|---|
40–49 | 10,757 | 6393 | 32 | 0.5% (0.4–0.7) | 54 | 5 | 0.08% (0.0–0.2) | 8 |
50–59 | 8861 | 5997 | 69 | 1.2% (0.9–1.5) | 102 | 24 | 0.4% (0.2–0.6) | 35 |
60–69 | 7129 | 5139 | 28 | 0.5% (0.4–0.8) | 39 | 4 | 0.08% (0.0–0.2) | 6 |
70–79 | 3898 | 2662 | 3 | 0.1% (0.0–0.3) | 4 | 0 | 0% (0.0–0.1) | 0 |
80–89 | 1620 | 708 | 2 | 0.3% (0.1–1.0) | 5 | 0 | 0% (0.0–0.5) | 0 |
90–104 | 326 | 47 | 0 | 0% (0.0–7.6) | 0 | 0 | 0% (0.0–7.6) | 0 |
Total | 32,591 | 20,946 | 134 | 0.6% (0.5–0.7) | 209 | 33 | 0.2% (0.1–0.3) | 51 |